人参皂苷对小鼠晚期乳腺癌模型的抑瘤作用

发布时间：2018-12-29 08:20

【摘要】：目的探究人参皂苷对小鼠晚期乳腺癌模型的抑瘤作用。方法小鼠适应性饲养1周后将4T1乳腺癌细胞悬液1 m L(1.0×1010L-1)接种于右胸部皮下建立晚期乳腺癌模型。30只BALB/c小鼠晚期乳腺癌模型随机分为模型组、环磷酰胺组、人参皂苷低剂量组、人参皂苷中剂量组和人参皂苷高剂量组,每组6只。环磷酰胺组小鼠给予环磷酰胺2 mg·kg-1,腹腔注射,隔日1次;人参皂苷低、中、高剂量组小鼠分别给予0.5、1.0、2.0 mg·kg-1的人参皂苷灌胃;模型组小鼠给予2 m L·kg-1的无菌生理盐水灌胃;灌胃均每日1次,连续4周。苏木精-伊红染色观察各组小鼠乳腺癌组织的病理改变,并比较各组小鼠的癌瘤质量、体积,抑瘤率,肺转移结节数及肿瘤转移抑制率。结果环磷酰胺组和人参皂苷低、中、高剂量组小鼠癌瘤质量和体积均显著小于模型组(P0.05),抑瘤率显著高于模型组(P0.05);人参皂苷中剂量组小鼠癌瘤质量、体积及抑瘤率与环磷酰胺组比较差异均无统计学意义(P0.05);人参皂苷高剂量组小鼠癌瘤质量和体积均显著小于环磷酰胺组(P0.05),抑瘤率显著高于环磷酰胺组(P0.05);人参皂苷中、高剂量组小鼠癌瘤质量和体积均显著小于人参皂苷低剂量组(P0.05),抑瘤率显著高于人参皂苷低剂量组(P0.05);人参皂苷高剂量组小鼠癌瘤质量和体积均小于人参皂苷中剂量组,抑瘤率高于人参皂苷中剂量组,但差异均无统计学意义(P0.05)。环磷酰胺组和人参皂苷低、中、高剂量组小鼠肺转移结节数显著少于模型组(P0.05),肺转移抑制率显著高于模型组(P0.05);人参皂苷中剂量组小鼠肺转移结节数及肺转移抑制率与环磷酰胺组比较差异均无统计学意义(P0.05);人参皂苷高剂量组小鼠肺转移结节数显著少于环磷酰胺组(P0.05),肺转移抑制率显著高于环磷酰胺组(P0.05);人参皂苷中、高剂量组小鼠肺转移结节数显著少于人参皂苷低剂量组(P0.05),肺转移抑制率显著高于人参皂苷低剂量组(P0.05);人参皂苷中、高剂量组小鼠肺转移结节数及肺转移抑制率比较差异均无统计学意义(P0.05)。结论人参皂苷能够显著抑制小鼠乳腺癌的发生、发展和转移。
[Abstract]:Objective to investigate the inhibitory effect of ginsenoside on advanced breast cancer in mice. Methods A model of advanced breast cancer was established by inoculating 4T1 breast cancer cell suspension 1 m L (1.0 脳 1010L-1 into the right chest subcutaneously in mice for one week. Thirty BALB/c mice with advanced breast cancer were randomly divided into model group and cyclophosphamide group. Ginsenoside low dose group, ginsenoside medium dose group and ginsenoside high dose group, 6 rats in each group. Mice in the cyclophosphamide group were intraperitoneally injected with cyclophosphamide for 2 mg kg-1, once every other day. The mice in the model group were given 2 mL kg-1 aseptic saline once a day for 4 weeks. The pathological changes of breast cancer in each group were observed by hematoxylin-eosin staining. The tumor mass, volume, tumor inhibition rate, the number of metastatic nodules of lung and the tumor metastasis inhibition rate were compared in each group. Results the tumor mass and volume of mice in the cyclophosphamide group and ginsenoside group were significantly lower than those in the model group (P0.05), and the tumor inhibition rate was significantly higher in the middle and high dose groups than in the model group (P0.05). There was no significant difference in tumor quality, volume and tumor inhibition rate between middle dose group and cyclophosphamide group (P0.05). The tumor mass and volume of high-dose ginsenoside group were significantly lower than that of cyclophosphamide group (P0.05), and the tumor inhibition rate was significantly higher than that of cyclophosphamide group (P0.05). In the ginsenoside group, the tumor mass and volume in the high-dose group were significantly lower than those in the low-dose group (P0.05), and the tumor inhibition rate was significantly higher than that in the low-dose group (P0.05). The tumor mass and volume of high dose group of ginsenoside were lower than that of middle dose group of ginsenoside, and the inhibition rate of tumor was higher than that of middle dose group of ginsenoside, but the difference was not statistically significant (P0.05). Cyclophosphamide group and ginsenoside group were low, the number of lung metastasis nodules in high dose group was significantly lower than that in model group (P0.05), the inhibition rate of lung metastasis was significantly higher than that of model group (P0.05). There was no significant difference in the number of pulmonary metastasis nodules and the inhibition rate of lung metastasis between the middle dose group and cyclophosphamide group (P0.05). The number of metastatic nodules in high dose group was significantly lower than that in cyclophosphamide group (P0.05), and the inhibition rate of lung metastasis was significantly higher than that of cyclophosphamide group (P0.05). In the ginsenoside group, the number of pulmonary metastasis nodules in the high-dose group was significantly less than that in the low-dose group (P0.05), and the inhibitory rate of lung metastasis was significantly higher than that in the low-dose group (P0.05). There was no significant difference in the number of pulmonary metastasis nodules and the inhibition rate of lung metastasis in the high dose group (P0.05). Conclusion ginsenoside can significantly inhibit the occurrence, development and metastasis of breast cancer in mice.
【作者单位】：南昌市第三医院乳腺肿瘤科;
【分类号】：R285.5;R-332

【参考文献】